A patient hands you a printout of a peptide “stack” they bought online and asks whether it is safe. Increasingly, that conversation lands in the nurse practitioner’s exam room — which is exactly why understanding what peptide therapy is has become a practical clinical skill, not a fringe curiosity. Peptide therapy is the clinical use of short chains of amino acids — signaling molecules the body already uses — to modulate specific physiologic pathways such as growth hormone release, tissue repair, metabolism, and sexual function.
For NPs, the challenge is that the public-facing information on peptide therapy is dominated by med-spa marketing and consumer health sites, with little written for the prescriber. This primer fills that gap: what peptides are, how they work, the major clinical classes you will encounter, how they are administered, who may be a candidate, and the high-level prescribing and monitoring considerations that keep this practice defensible.
What Are Peptides? Signaling Molecules, Not Steroids
Peptides are short chains of amino acids — typically defined as 2 to 50 amino acids — linked by peptide bonds.[^statpearls-peptide] Proteins are longer chains; peptides sit between single amino acids and full proteins on the size spectrum. The body produces thousands of endogenous peptides that act as hormones, neurotransmitters, growth factors, and immune modulators. Insulin, glucagon, oxytocin, and the GLP-1 family are all peptides you already prescribe or encounter.
The clinical distinction that matters most for patient counseling: therapeutic peptides are signaling molecules, not anabolic steroids. Steroids are lipid-derived hormones that diffuse into the cell and act on intracellular (nuclear) receptors to regulate gene transcription; peptide hormones are amino-acid based and generally cannot cross the cell membrane, so they act by binding cell-surface receptors and triggering intracellular second-messenger cascades.[^statpearls-hormones][^ncbi-hormone-effects] “Are peptides steroids?” is one of the most-searched peptide questions, and the answer — no — is a useful starting point for any patient conversation.
How Does Peptide Therapy Work?
Peptide therapy works by supplying a peptide that mimics or amplifies an endogenous signal, prompting the body to produce a downstream effect rather than replacing an end hormone outright. A growth-hormone secretagogue, for example, does not deliver growth hormone — it acts on the pituitary to promote release of the patient’s own growth hormone in a pulsatile pattern that remains subject to the body’s normal negative-feedback regulation.[^ghs-review] This “upstream” mechanism is part of why secretagogues are often framed as more physiologic than exogenous growth hormone, though that framing should be presented cautiously and not as an efficacy or safety guarantee.
Their specificity — each peptide tends to act on a defined receptor or pathway — is what gives the class its appeal and also what makes class-by-class clinical knowledge essential. Understanding what peptide therapy does at the mechanism level is the foundation for everything that follows, including which patients are appropriate and what to monitor. For a deeper look at protocols built around these mechanisms, see our overview of clinical peptide protocols.
The Major Clinical Classes of Peptide Therapy
Most peptides an NP will encounter fall into a handful of functional classes. This section is a map, not a protocol — each class has a dedicated deep-dive that covers indications, evidence, dosing, and monitoring in detail.
Growth Hormone Secretagogues
This class — including sermorelin, ipamorelin, and CJC-1295 — stimulates endogenous growth hormone release and is used off-label for body composition, recovery, and sleep quality. None of these agents is FDA-approved for anti-aging or body-composition indications, and they reach patients only through compounding; their availability through compounding pharmacies is itself constrained and varies by substance.[^fda-503a-bulks] These agents differ meaningfully in half-life and selectivity, which drives how they are combined and dosed. See the deep-dive: Sermorelin vs. Ipamorelin vs. CJC-1295.
Healing & Recovery Peptides
BPC-157 and TB-500 (thymosin beta-4) are the best-known “recovery” peptides. Their evidence base for tissue repair, tendon and ligament healing, and gastrointestinal protection is predominantly preclinical — drawn from animal and in-vitro models — with human clinical data remaining limited.[^bpc-review] Their regulatory status is a frequent point of confusion: neither is an FDA-approved drug, and BPC-157 in particular has been placed by the FDA in the category of bulk substances that raise significant safety concerns and are not currently eligible for use in compounding under section 503A.[^fda-503a-bulks] See the deep-dive: BPC-157 & TB-500 recovery peptides.
Metabolic Peptides
The GLP-1 (and dual GIP/GLP-1) receptor agonists semaglutide and tirzepatide are the FDA-approved heavyweights of this class. Semaglutide is FDA-approved both for glycemic control in type 2 diabetes (Ozempic) and for chronic weight management (Wegovy), and tirzepatide is likewise FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound).[^fda-ozempic][^fda-wegovy] They are covered in depth across Elite NP’s weight-management resources rather than here, and they illustrate the most established, evidence-backed end of the peptide spectrum. For prescriber-level training on GLP-1 and weight-loss peptide protocols, see Elite NP’s Definitive Weight Loss Course.
Sexual-Health Peptides
PT-141 (bremelanotide) acts on melanocortin receptors to influence sexual desire and is notable as one of the few peptides in this cluster with an FDA-approved formulation. Marketed as Vyleesi, bremelanotide is FDA-approved (initial approval 2019) for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD); it is not approved for HSDD in postmenopausal women or in men.[^fda-vyleesi] See the deep-dive: PT-141 (bremelanotide) for NPs.
Cosmetic & Longevity Peptides
This emerging group — NAD+ precursors, epitalon, and others marketed for “anti-aging” and cellular longevity — has the most enthusiastic marketing and the thinnest high-quality human evidence. Human-outcome data for these agents remain limited and are drawn largely from small, short, or preclinical studies, and they are generally not FDA-approved for anti-aging or longevity indications.[^epitalon-review][^nad-review] It is the cluster’s namesake and demands the most careful counseling. See the deep-dive: Anti-aging & longevity peptides.
Routes of Administration
Because peptides are degraded by acid and proteolytic enzymes in the gastrointestinal tract and cross the intestinal wall poorly, the oral bioavailability of most peptides is low — which is why subcutaneous injection is the dominant route for clinical peptides.[^delivery-review] Patients self-administer with small-gauge insulin-style syringes, typically rotating sites in the abdomen.
Other routes appear in practice and in compounded products: intranasal (used for some melanocortin and nootropic peptides), oral or sublingual (a small number of peptides formulated for limited absorption), and topical (notably cosmetic copper peptides such as GHK-Cu). Route matters for counseling because it drives onset, dosing frequency, and adherence — all of which feed into the monitoring plan discussed below.
Who Is a Candidate — and Who Is Not?
Candidate selection is a clinical judgment, not a checkbox. Broadly, peptide therapy is considered for adults seeking support for recovery, body composition, metabolic health, sexual function, or healthy aging who have realistic expectations and no contraindicating conditions. As a general principle of responsible prescribing — and especially because many peptides are used off-label or are compounded — a thorough history, an appropriate baseline assessment (including relevant labs for the class being considered), and a documented informed-consent conversation are sound practice.[^ghs-review] The specific workup should be individualized to the patient and the peptide class; detailed, class-by-class candidacy and screening protocols are covered in the course.
Peptide therapy should be avoided in patients who are planning pregnancy, currently pregnant, or breastfeeding — the safety of these agents in pregnancy and lactation has not been established, and they are not appropriate while a patient is trying to conceive or nursing. Caution or avoidance is likewise warranted in patients with active or recent malignancy: growth-hormone secretagogues raise insulin-like growth factor-1 (IGF-1), and because the GH/IGF-1 axis can promote cell proliferation, active or recent cancer is a recognized concern for growth-promoting peptides.[^ghs-review][^ghs-igf1] Avoidance also applies to anyone unable to consent to the off-label and evidence-limited nature of many of these agents. This is also where scope of practice intersects with prescribing: NP scope of practice and compounding/prescribing authority vary by state, so confirm that the specific peptide and route fall within your authority with your state Board of Nursing (and, where relevant, Board of Pharmacy) before initiating therapy.
Prescribing & Monitoring Considerations for NPs
At a high level, responsible peptide prescribing rests on four pillars: a defensible indication, a legitimate sourcing pathway, baseline-and-follow-up monitoring, and documented informed consent. Sourcing is the pillar most likely to create regulatory exposure. Use only FDA-approved products or peptides compounded by a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility. Under the Federal Food, Drug, and Cosmetic Act, 503A compounding is done by a licensed pharmacist or physician for an individual patient, while 503B outsourcing facilities register with the FDA and compound under current good manufacturing practice (CGMP) requirements.[^fda-compounding] Never use research-use-only (“RUO” / “for research use only”), “research-grade,” or black-market peptides — products labeled “for research use only” are, by definition, not intended for human or clinical use, carry no assurance of identity, purity, sterility, or potency, and using them exposes both patient and prescriber to serious safety and legal risk.[^fda-ruo] For the legal and FDA-status nuances behind sourcing, see Elite NP’s guide to the FDA status of peptides.
Monitoring depends on the class and should be individualized. Because growth-hormone secretagogues act through the GH/IGF-1 axis and GH can affect glucose metabolism, follow-up for that class commonly includes attention to IGF-1, glucose, and symptom response;[^ghs-review][^ghs-igf1] metabolic peptides follow the established GLP-1 monitoring framework; and recovery and cosmetic peptides are monitored largely clinically. Across all classes, the prescriber should track efficacy against the stated goal, screen for adverse effects, and reassess the risk-benefit calculus at defined intervals. Building this structured competency — indication, sourcing, dosing, and the specific monitoring parameters for each class — is the core of formal training such as the Anti-Aging & Peptide Course, which is designed specifically for the NP prescriber.
Frequently Asked Questions About Peptide Therapy
What is peptide therapy in simple terms?
Peptide therapy is the clinical use of short amino-acid chains — called peptides — to influence specific body processes such as growth hormone release, tissue repair, metabolism, and sexual function. Because peptides are signaling molecules the body already uses, the goal is usually to amplify or mimic a natural signal rather than replace a hormone outright. Most clinical peptides are given by subcutaneous injection.
Are peptides the same as steroids?
No. Peptides are short chains of amino acids that typically act on cell-surface receptors, while anabolic steroids are lipid-based hormones that act inside the cell on nuclear receptors. They are different classes of molecules with different mechanisms, uses, and risk profiles. This distinction is one of the most common points of patient confusion.[^statpearls-hormones]
How is peptide therapy administered?
Most peptides are administered by subcutaneous injection because they are broken down in the digestive tract and have poor oral absorption. Some peptides are also delivered intranasally, sublingually, or topically depending on the molecule. The route affects dosing frequency, onset, and patient adherence.[^delivery-review]
Are peptides FDA-approved?
Some are. Certain peptides — including GLP-1 receptor agonists like semaglutide and the sexual-health peptide bremelanotide — have FDA-approved formulations for specific indications, while many popular “wellness” peptides are not FDA-approved and reach patients through compounding pharmacies.[^fda-ozempic][^fda-vyleesi] Confirming the regulatory status of a specific peptide is an essential prescribing step. See Elite NP’s FDA status of peptides guide, and for GLP-1 and weight-loss peptides specifically, the Definitive Weight Loss Course.
Do nurse practitioners need special training to offer peptide therapy?
There is no single national peptide-therapy credential required to prescribe; NP scope of practice and prescriptive authority are set state by state, so verify the rules that apply to you with your state Board of Nursing. That said, structured training is strongly recommended because most peptide prescribing involves off-label use, compounded products, and class-specific monitoring. A dedicated course helps NPs build defensible competency in candidate selection, sourcing, dosing, and monitoring. Elite NP’s Anti-Aging & Peptide Course is built for the NP prescriber.
Conclusion
Peptide therapy uses the body’s own signaling molecules to target recovery, metabolism, hormone optimization, sexual health, and longevity — but the clinical reality spans a wide range, from FDA-approved agents to evidence-thin, compounded products. For nurse practitioners, the takeaways are clear: know the mechanism, know the class, verify the source, and monitor by indication. As patient demand grows, NPs who understand peptides are positioned to lead these conversations safely and credibly.
Ready to build prescriber-level competency? The Elite NP Anti-Aging & Peptide Course translates this primer into practice for the NP clinician.
Sources
All sources accessed June 26, 2026.
Forbes J, Krishnamurthy K. Biochemistry, Peptide. In: StatPearls. Treasure Island (FL): StatPearls Publishing; updated 2023. NCBI Bookshelf NBK562260. https://www.ncbi.nlm.nih.gov/books/NBK562260/ (“A peptide is a short string of 2 to 50 amino acids.”)
Hiller-Sturmhöfel S, et al. Biochemistry, Hormones. In: StatPearls. Treasure Island (FL): StatPearls Publishing. NCBI Bookshelf NBK541112. https://www.ncbi.nlm.nih.gov/books/NBK541112/ (Peptide/amino-acid–derived hormones act at cell-surface receptors; steroid hormones act on intracellular/nuclear receptors.)
Siegelbaum SA, Hudspeth AJ. Classification of Hormonal Effects. In: Basic Neurochemistry. NCBI Bookshelf NBK28055. https://www.ncbi.nlm.nih.gov/books/NBK28055/ (Peptide hormones act on cell-surface receptors via second-messenger systems such as cAMP, Ca²⁺/calmodulin, and phosphoinositides.)
Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45–53. PMC5632578. https://pmc.ncbi.nlm.nih.gov/articles/PMC5632578/ (Growth hormone secretagogues promote pulsatile GH release that remains subject to negative feedback; review of safety, monitoring, and IGF-1 considerations.)
Sigalos JT, et al. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. Am J Mens Health. 2017. PMC5675260. https://pmc.ncbi.nlm.nih.gov/articles/PMC5675260/ (GH secretagogues raise serum IGF-1.)
A Narrative Review of BPC-157 for Musculoskeletal Healing (“Regeneration or Risk?”). PMC12446177. https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/ (Evidence for BPC-157/thymosin beta-4 in tissue repair is largely preclinical; human clinical data remain limited.)
Brown TD, et al. Barriers and Strategies for Oral Peptide and Protein Therapeutics Delivery. PMC12030352. https://pmc.ncbi.nlm.nih.gov/articles/PMC12030352/; see also Approaches for Enhancing Oral Bioavailability of Peptides and Proteins, PMC3680128 https://pmc.ncbi.nlm.nih.gov/articles/PMC3680128/ (Pre-systemic enzymatic degradation and poor intestinal permeability give most peptides low oral bioavailability, making parenteral — typically subcutaneous — administration the standard route.)
U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, and Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act and https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks (BPC-157 placed in the category of nominated bulk substances raising significant safety concerns and not eligible for compounding under the 503A interim policy; sermorelin/ipamorelin/CJC-1295 are not FDA-approved drugs.)
U.S. Food and Drug Administration, Drugs@FDA. Ozempic (semaglutide) injection, NDA 209637, approved December 2017 — indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. FDA approval letter: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/209637s000ltr.pdf; label via DailyMed (setid adec4fd2-6858-4c99-91d4-531f5f2a2d79): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79. Tirzepatide is FDA-approved as Mounjaro for type 2 diabetes (NDA 215866, approved May 13, 2022) and as Zepbound for chronic weight management (FDA news release: https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management).
U.S. Food and Drug Administration, Drugs@FDA. Wegovy (semaglutide) injection, NDA 215256, approved June 4, 2021 — indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management. FDA approval letter: https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/215256Orig1s000ltr.pdf.
U.S. Food and Drug Administration. VYLEESI (bremelanotide injection), Initial U.S. Approval 2019 — indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD); not indicated in postmenopausal women or men. FDA label (NDA 210557): https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf; label via DailyMed (setid 8c9607a2-5b57-4a59-b159-cf196deebdd9): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c9607a2-5b57-4a59-b159-cf196deebdd9.
Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Properties. PMC11943447. https://pmc.ncbi.nlm.nih.gov/articles/PMC11943447/ (Human-outcome evidence for epitalon is limited and drawn largely from small or preclinical studies; not FDA-approved for anti-aging/longevity indications.)
Conlon N, Ford D. Clinical Evidence for Targeting NAD Therapeutically. PMC7558103. https://pmc.ncbi.nlm.nih.gov/articles/PMC7558103/ (Human clinical evidence for NAD-boosting interventions remains limited relative to preclinical data.)
U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers; FD&C Act Provisions That Apply to Human Drug Compounding. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers and https://www.fda.gov/drugs/human-drug-compounding/fdc-act-provisions-apply-human-drug-compounding (Section 503A: compounding by a licensed pharmacist/physician for an identified patient, exempt from CGMP and FDA premarket approval; Section 503B: registered outsourcing facilities compound under CGMP requirements.)
U.S. Food and Drug Administration. Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only — Guidance for Industry and FDA Staff. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/distribution-in-vitro-diagnostic-products-labeled-research-use-only-or-investigational-use-only (Products labeled “For Research Use Only. Not for use in diagnostic [or clinical] procedures” are not intended for human/clinical use.)
